Trial record 1 of 1 for:    NCT01737814
Previous Study | Return to List | Next Study

Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC) (EPIC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01737814
Recruitment Status : Completed
First Posted : November 30, 2012
Last Update Posted : October 28, 2016
Information provided by (Responsible Party):
Mast Therapeutics, Inc.

Brief Summary:
The purpose of this study is to evaluate whether MST-188 can reduce the duration of vaso-occlusive crisis (VOC) in subjects with sickle cell disease. The study will also evaluate whether MST-188 can reduce the frequency of rehospitalization of subjects due to a recurrence of VOC. Additionally, this study will compare the development of acute chest syndrome during VOC in subjects who receive MST-188 to those who do not receive MST-188.

Condition or disease Intervention/treatment Phase
Vaso-occlusive Crisis Sickle Cell Disease Drug: Saline Drug: MST-188 Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 388 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC): A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial of MST-188 (Purified Poloxamer 188) Injection in Subjects With Sickle Cell Disease Experiencing Vaso Occlusive Crisis
Study Start Date : May 2013
Primary Completion Date : February 2016

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: MST-188
MST-188 injection administered as a continuous infusion 100 mg/kg for 1 hour followed by 30 mg/kg/hr for up to 48 hours.
Drug: MST-188
Other Name: vepoloxamer
Placebo Comparator: Saline
Saline administered as a continuous infusion for up to 49 hours
Drug: Saline

Primary Outcome Measures :
  1. Reduction of the duration of vaso occlusive crisis (VOC) in subjects with sickle cell disease. [ Time Frame: Study participants will be followed for the duration of hospital stay, an expected average of 4 days ]

Secondary Outcome Measures :
  1. Re-hospitalization rate for VOC [ Time Frame: Hospital discharge to 14 days post-discharge ]
  2. Occurence of acute chest syndrome [ Time Frame: Randomization to 120 hours after randomization ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   4 Years to 65 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age 4 through 65 years
  • Subject has a confirmed diagnosis of HbSS, HbSC, HbSβ+thal, or HbSβ0thal
  • Subject is experiencing acute pain typical of vaso-occlusive crisis requiring treatment with parenteral analgesia
  • Subject requires hospitalization

Exclusion Criteria:

  • Subject has acute chest syndrome
  • Subject's laboratory results indicate inadequate organ function
  • Subject is pregnant or nursing an infant
  • Subject had a painful crisis requiring hospitalization within the preceding 14 days or has experienced > 5 hospitalizations for VOC in the prior 6 months
  • Subject has been transfused within the past 14 days
  • Subject is hospitalized for a condition other than VOC
  • Subject has complications related to SCD

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01737814

  Hide Study Locations
United States, Alabama
University of South Alabama
Mobile, Alabama, United States, 36688
United States, Arizona
Phoenix Children's Hospital
Phoenix, Arizona, United States, 85016
United States, California
UCSF Benioff Children's Hospital
Oakland, California, United States, 94609
University of California Davis Health System
Sacramento, California, United States, 95817
Rady Children's Hosptial
San Diego, California, United States, 92123
Harbor-UCLA Medical Center
Torrence, California, United States, 90502
United States, Delaware
Al DuPont Hospital for Children
Wilmington, Delaware, United States, 19803
United States, District of Columbia
Howard University
Washington, District of Columbia, United States, 20060
United States, Florida
Children's Hospital of SouthWest Florida
Fort Myers, Florida, United States, 33908
Joe Dimaggio Children's Hospital
Hollywood, Florida, United States, 33021
University of Miami
Miami, Florida, United States, 33136
Miami Children's Hospital
Miami, Florida, United States, 33155
All Children's Hospital
St. Petersburg, Florida, United States, 33701
Tampa General Hospital
Tampa, Florida, United States, 33606
United States, Georgia
Grady Memorial Hospital
Atlanta, Georgia, United States, 30303
Georgia Regents University
Augusta, Georgia, United States, 30912
United States, Illinois
Ann and Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois, United States, 60611
Children's Hospital at the University of Illinois
Chicago, Illinois, United States, 60612
United States, Indiana
Fort Wayne Lutheran Hospital
Ft. Wayne, Indiana, United States, 46804
Riley Hospital for Children
Indianapolis, Indiana, United States, 46202
United States, Iowa
University of Iowa-Children's Hospital
Iowa City, Iowa, United States, 52242
United States, Kentucky
University of Louisville/Kosair Children's Hospital
Louisville, Kentucky, United States, 40202
United States, Louisiana
Our Lady of the Lake Children's Hospital
Baton Rouge, Louisiana, United States, 70808
Children's Hospital of New Orleans
New Orleans, Louisiana, United States, 70118
United States, Maryland
Johns Hopkins
Baltimore, Maryland, United States, 21205
The Herman and Walter Samuelson Children's Hospital at Sinai
Baltimore, Maryland, United States, 21215
United States, Michigan
Children's Hospital of Michigan-Wayne State University
Detroit, Michigan, United States, 48201
Hurley Research Center
Flint, Michigan, United States, 48503
United States, Mississippi
University of Mississippi Medical Center
Jackson, Mississippi, United States, 39216
United States, New Jersey
Rutger's University
New Brunswick, New Jersey, United States, 08903
United States, New York
Bronx Lebanon Hospital
Bronx, New York, United States, 10457
NY Methodist
Brooklyn, New York, United States, 11215
Cohen Children's Medical Center
New Hyde Park, New York, United States, 11040
Golisano Children's Hospital at URMC
Rochester, New York, United States, 14642
United States, North Carolina
University of North Carolina-Chapel Hill
Chapel Hill, North Carolina, United States, 27599
Duke University Medical Center
Durham, North Carolina, United States, 27710
East Carolina University
Greenville, North Carolina, United States, 27834
United States, Ohio
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States, 45229
Rainbow Babies and Children's Hospital
Cleveland, Ohio, United States, 44106
United States, Oregon
Randall Children's Hospital
Portland, Oregon, United States, 97227
United States, Pennsylvania
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States, 19104
Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania, United States, 15224
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States, 15232
United States, South Carolina
The Medical University of South Carolina
Charleston, South Carolina, United States, 29425
United States, Tennessee
T.C. Thompson Children's Hospital
Chattanooga, Tennessee, United States, 37403
United States, Texas
Cook's Children Hospital
Fort Worth, Texas, United States, 76104
Texas Children's Hospital
Houston, Texas, United States, 77030
United States, Virginia
University of Virginia Medical Center
Charlottsville, Virginia, United States, 22908
Children's Hospital of the King's Daughters
Norfolk, Virginia, United States, 23507
Children's Hospital of Richmond
Richmond, Virginia, United States, 23298
Reearch Center
Antwerp, Belgium
Research Center
Brussels, Belgium
Research Center
Edgem, Belgium
Research Center
Liege, Belgium
Research Center
Montegnee, Belgium
Resaerch Center
Rio de Janerio, Brazil
Research Center
Sao Paulo, Brazil
Dominican Republic
Research Center
Santo Domingo, Dominican Republic, 10101
Research Center
Santo Domingo, Dominican Republic, 10514
Research Center
Kingston, Jamaica
Research Center
Irbid, Jordan
Research Center
Beirut, Lebanon
Research Center
Tripoli, Lebanon
Research Center - Child Health Department
Muscat, Oman
Research Center
Muscat, Oman
Research Center Hospital del Nino
Panama, Panama
Research Center Hospital of Pediatric Specialities
Panama, Panama
Research Center Metropolitan Hospital
Panama, Panama
Research Center
Madrid, Spain
Research Center
Adana, Turkey
Research Center
Istanbul, Turkey
Research Center
Mersin, Turkey
Sponsors and Collaborators
Mast Therapeutics, Inc.
Study Director: Edwin L. Parsley, D.O. Mast Therapeutics, Inc.

Responsible Party: Mast Therapeutics, Inc. Identifier: NCT01737814     History of Changes
Other Study ID Numbers: MST-188-01
First Posted: November 30, 2012    Key Record Dates
Last Update Posted: October 28, 2016
Last Verified: October 2016

Keywords provided by Mast Therapeutics, Inc.:
sickle cell disease
vaso-occlusive crisis

Additional relevant MeSH terms:
Anemia, Sickle Cell
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Hematologic Diseases
Genetic Diseases, Inborn